| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04134442 Details | 2022-07-06 Interventional | 4 | 0 | Bupivacaine Pain, Postopera… Shoulder Pain Osteoarthritis … | A new large meta-analysis was published. The results showed the likelihood that liposomal
bupivacaine and nerve blocks no longer offer significant contribution. Decision was made to
terminate the study. - | |||
| NCT03591874 Details | 2022-07-06 Interventional | 3 | 59 | Brimonidine Tar… Graft vs Host D… Brimonidine Tar… Graft Versus Ho… Lubricant Eye D… Ocular Graft vs… Ocular Surface … Ophthalmic Solu… oGVHD | Primary endpoint was not met. - | |||
| NCT02683941 2015-004992-62 Details | 2022-07-06 Interventional | 3 | 77 | Lanreotide Somatostatin Neuroendocrine … Neuroendocrine … | National Comprehensive Cancer Network & European Neuroendocrine Tumor Society guidelines
(2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby
limiting recruitment. The majority of subjects who entered the open-label treatment phase were withdrawn due to study termination by the sponsor. | |||
| NCT04512261 Details | 2022-07-01 Interventional | 1/2 | 0 | Pembrolizumab Trastuzumab Tucatinib Brain Neoplasms Breast Neoplasm… Central Nervous… Neoplasm Metast… Brain Metastase… Breast Cancer CNS Disease HER2-positive B… | Study withdrawn due to change in treatment landscape for HER2+ metastatic breast cancer. - | |||
| NCT04093505 Details | 2022-07-01 Interventional | 3 | 28 | Gemtuzumab Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Study turned out no longer feasible. End of Recruitment: 25.5.2022 - | |||
| NCT04006847 Details | 2022-07-01 Interventional | 1/2 | 1 | Bosutinib Dasatinib Nilotinib Tyrosine Kinase… Leukemia Leukemia, Myelo… Leukemia, Myelo… Chronic Myeloid… | Product complaint Due to the product issues, the trials was halted. | |||
| NCT03502681 Details | 2022-07-01 Interventional | 1 | 6 | Avelumab Metastatic Urot… | Funder Decision Due to the early termination of the study, no primary or secondary endpoints were analyzed. | |||
| NCT01156220 Details | 2022-07-01 Interventional | 4 | 0 | Furosemide Healthy Male an… | Study was never implemented. - | |||
| NCT04343248 Details | 2022-06-30 Interventional | 3 | 190 | Nitazoxanide COVID-19 Viral Respirato… | Study recruitment was halted prematurely as widespread vaccination of the study population made
completion infeasible. - | |||
| NCT04895046 Details | 2022-06-29 Interventional | 2 | 0 | Dostarlimab Niraparib Cholangiocarcin… HRD Metastatic Canc… | Funder decision - | |||
| NCT04191382 2019-002015-26 Details | 2022-06-29 Interventional | 2 | 105 | Letrozole Breast Neoplasm… Breast Cancer | early discontinuation based on strategic sponsor decision not driven by any safety concerns The study recruitment discontinued early based on strategic sponsor decision that was not driven by any safety concerns. No inferential statistical analysis was performed due to early termination. | |||
| NCT03563742 Details | 2022-06-29 Interventional | 3 | 58 | Lamivudine Rilpivirine Tenofovir Acquired Immuno… Communicable Di… HIV Infections Immunologic Def… Infections Human Immunodef… | High SF rate (less treatment-naïve subjects & subjects with viral load <100000). Reevaluation
in scientific position in India after internal discussion. - | |||
| NCT02663908 Details | 2022-06-29 Interventional | 3 | 545 | Leuprolide Cardiovascular … Prostatic Neopl… Prostate Cancer | Recruitment rate; a lower than anticipated observed cardiovascular event rate. The Sponsor
decision to stop the trial was not based on any safety concerns or any knowledge of the
results, or influenced by issues imposed by the COVID-19 pandemic. The trial was terminated prematurely due to a slower than anticipated recruitment rate and a lower than anticipated observed CV event rate. Approximately 900 patients were planned to be included, however, at the time of stopping screening and recruitment 216 patients had completed the trial, 292 were ongoing, and 37 were withdrawn. The Sponsor decision to stop the trial was not based on any safety concerns, any knowledge of the results, or influenced by issues imposed by the COVID-19 pandemic. | |||
| NCT01398852 Details | 2022-06-29 Interventional | 3 | 500 | Riboflavin Dilatation, Pat… Keratoconus Keratoconus and… | - - | |||
| NCT01398839 Details | 2022-06-29 Interventional | 3 | 103 | Riboflavin Dilatation, Pat… Ectasia | - - | |||
| NCT03584009 2017-005118-74 Details | 2022-06-28 Interventional | 2 | 103 | Fulvestrant Venetoclax Breast Neoplasm… Recurrence Estrogen Recept… | Sponsor's decision, no safety concerns. The study was terminated due to Sponsor's decision and there were no safety concerns. Primary and secondary efficacy endpoints have been updated to report 95% confidence interval (CI) for Clinical Benefit estimate and 95% CI for the Cox proportional hazards model for PFS, following reporting conventions. | |||
| NCT01177540 Details | 2022-06-28 Interventional | 2 | 25 | Decitabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Pediatric Acute… | The study was terminated early due to enrollment difficulties and the futility of observing
differences in remission rate between treatment arms. The study was terminated early due to enrollment difficulties and the futility of observing differences in remission rate between treatment arms. | |||
| NCT03783923 Details | 2022-06-27 Interventional | 3 | 11 | Deflazacort Muscular Dystro… Muscular Dystro… Limb-Girdle Mus… | The study was terminated early due to low enrollment and missing efficacy assessment data due
to missed visits related to COVID-19. The study was terminated early due to low enrollment and missing efficacy assessment data due to missed visits related to COVID-19. | |||
| NCT04066478 Details | 2022-06-23 Interventional | 2/3 | - | Dehydroepiandro… Infertility Infertility, Fe… Poor Response t… | Sponsor - | |||
| NCT01397201 2010-023168-41 Details | 2022-06-23 Interventional | 2 | 30 | Fluticasone Xhance Asthma | - Study was terminated by the decision of the sponsor. As limited data were collected due to early termination and only limited number of patients completed the 8-week treatment period, no analysis of primary and secondary endpoint were conducted. |